Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2006

View Archived Issues

Tanabe Seiyaku updates pipeline status

Angiostatin, endostatin and saxatilin gene cotransfection blocks tumor growth in vivo

Durect reveals intended milestones for 2006

New phase II trial investigates bicifadine for osteoarthritis

Targeting the Sonic hedgehog pathway for CNS pathology in Down's syndrome

Nabi vaccines stimulate antibody responses in phase I trials

Australian centers to study new therapeutics vaccine for genital warts

New inhibitory peptide targets SARS-CoV spike protein to block infectivity

Elan to sell European Prialt rights to Eisai

DOR preparing regulatory submissions for orBec in iGVHD

Ceragenix enters CRADA with CDC to evaluate Ceracide in biofilm prevention

Zonagen seeks stockholder approval to change name to Repros Therapeutics

Igeneon and Celltrion sign letter of intent to amend IGN-311 agreement

ALGRX-4975 completes postsurgery phase II studies

MERLIN study of Ranexa cleared to continue

Genzyme launches test to monitor Gleevec resistance

Results of INFUSE-LR study of Hylenex

NeoPharm updates progress of LEP-ETU

Medivir designates candidate drug from HIV NNRTI program

New potent and selective HCV polymerase inhibitors are effective against multiple genotypes

Ras plays an important tumorgenic role in the liver

Recent GSK patents report new treatments for psychotic disorders

New therapeutics for cancer covered in recent patent literature

Rituxan approved with CHOP for diffuse large B-cell NHL

New data presented on PEDF gene therapy for age-related macular degeneration / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...